Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice

Fig. 1

A treatment algorithm based on cardiac and renal co-morbidities and CVOTs. 1To be used with caution because of the risk of hypoglycemia; 2consider dose reduction (except for linagliptin) and monitor eGFR frequently; 3preferred in the presence of marked insulin resistance; 4initiation of therapy currently not recommended. aUKPDS; bPROACTIVE trial; cSAVOR; dTECOS, eEXAMINE; fLEADER trial; gEMPA-REG Outcome trial; hORIGIN trial; kADVANCE; jELIXA; mDIGAMI 1

Back to article page